Chapter 1 : Introduction

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Introduction, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815523/9781555814380_Chap01-1.gif /docserver/preview/fulltext/10.1128/9781555815523/9781555814380_Chap01-2.gif


This is an introductory chapter to the book Aspergillus fumigatus and Aspergillosis. Fast forwarding to the present, one can now recognize aspergillosis as afflicting 10 to 15% of patients with solid organ or allogeneic hematopoietic stem cell transplants and of leukemic patients, and it is also not an uncommon infection in advanced AIDS. While infections due to the other major opportunistic group of fungi, Candida species, have reached a plateau, the infection rate due to Aspergillus species keeps rising. Moreover, Aspergillus pathogenicity is currently recognized in intensive care patients who are not immunocompromised in the classic senses of neutropenia or neutrophil dysfunction or having received cytotoxic or immunosuppressive therapy. Biomedical scientists and physicians have now had to make large investments in the effort to respond to this rising wave of cases, tragic waste of lives, and burden of health care costs. Appreciation of patterns in imaging with newer radiographic techniques and/or detection of galactomannan, glucan, or DNA by PCR in samples of blood or other body fluids has brought one to the position of being able to use one's therapeutic armory at a more opportune, early time in a patient’s infection. The chapter provides an insight into what follows in this volume - expositions, by current leaders, of the present knowledge. They tell us of our present understanding of the structure of the taxon, the methods of reproduction and growth, and its genes and how they are expressed in metabolism and development.

Citation: Stevens D. 2009. Introduction, p 1-3. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch1
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Ascioglu, S.,, J. H. Rex,, B. de Pauw,, J. E. Bennett,, J. Bille,, F. Crokaert,, D. W. Denning,, J. P. Donnelly,, J. E. Edwards,, Z. Erjavec,, E. Fiere,, O. Lortholary,, J. Maertens,, J. F. Meis,, T. Patterson,, J. Ritter,, D. Sellesag,, P. M. Shah,, D. A. Stevens, and, T. J. Walsh. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplantation: an international consensus. Clin. Infect. Dis. 34: 714.
2. Clemons, K. V., and, D. A. Stevens. 2005. Contributions of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med. Mycol. 43(Suppl. 1): S101S110.
3. Dasbach, E. J.,, G. M. Davies, and S. M. Teutsch. 2000. Burden of aspergillosis-related hospitalizations in the United States. Clin. Infect. Dis. 31: 15241528.
4. Denning, D. W.,, R. M. Tucker,, L. H. Hanson, and D. A. Stevens. 1989. Treatment of invasive aspergillosis with itraconazole. Am. J. Med. 89: 791800.
5. Henrici, A. T. 1939. An endotoxin from Aspergillus fumigatus. J. Immunol. 36: 319338.
6. Herbrecht, R.,, D. W. Denning,, T. F. Patterson,, J. E. Bennett,, R. E. Greene,, J. W. Oestmann,, W. V. Kern,, K. A. Marr,, P. Ribaud,, O. Lortholary,, R. Sylvester,, R. H. Rubin,, J. R. Wingard,, P. Stark,, C. Durand,, D. Caillot,, E. Thiel,, P. H. Chandrasekar,, M. R. Hodges,, H. T. Schlamm,, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347: 408415.
7. Latgé, J.-P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Micro-biol. Rev. 12: 310350.
8. Lin, S. J.,, J. Schranz, and S. M. Teusch. 2001. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32: 358366.
9. Steinbach, W. J.,, J.-P. Latgé, and D. A. Stevens (ed.). 2005. Advances against aspergillosis. Proceedings of the Advances Against Aspergillosis Conference 9–11 September, 2004, San Francisco, USA. Med. Mycol. 43(Suppl. 1): S1S319.
10. Steinbach, W. J., and, D. A. Stevens. 2003. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin. Infect. Dis. 37(Suppl. 3): S157S187.
11. Steinbach, W. J.,, D. A. Stevens,, K. V. Clemons,, J.-P. Latgé, and R. B. Moss (ed.). 2006. Proceedings of the 2nd Advances Against Aspergillosis Conference, 22–25 February, 2006, Athens, Greece. Med. Mycol. 44(Suppl. 1): S1S392.
12. Steinbach, W. J.,, D. A. Stevens,, D. W. Denning, and R. B. Moss (ed.). 2003. Advances against aspergillosis. Clin. Infect. Dis. 37(Suppl. 3): S155S292.
13. Stevens, D. A., and, J. Y. Lee. 1997. Analysis of compassionate use itraconazole therapy of invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch. Intern. Med. 157: 18571862.
14. Vanden Bossche,, H.,, D. W. R. Mackenzie, and G. Cauwenbergh (ed.). 1988. Aspergillus and Aspergillosis. Plenum Press, New York, NY.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error